Figure 1 Generation and selection of mAbs against cFBG. (A) The sequences of position 1–49 and 241–284 of the fibrinogen Aα chain are shown, and the sequences of R16R and R252R are underlined. The mRNA encoded fibrinogen is modified post‐translationally and at the point indicated by an arrow the secreted form of fibrinogen starts. R16R and R252R, respectively, correspond to positions 11–21 and 247–257 of the secreted fibrinogen Aα chain. R16Cit and R252Cit, used as antigens for mAbs, have citrulline substituted from arginine at position 16 and 252, respectively. Fibrinopeptide A is indicated by italics. (B–D) Selection of the mAbs against cFBG. The enzymatic modification was confirmed by sodium dodecyl sulphate‐polyacrylamide gel electrophoresis (SDS‐PAGE) followed by (B) Coomassie brilliant blue staining and western blotting using (C) the anti‐modified citrulline (AMC) antibody and (D) mAbs cF16.1 and cF252.1. Lane 1, cFBG; lane 2, nFBG; lane 3, fibrinogen treated by rabbit PADI2 as in lane 1, with EDTA added before treatment.